MetaADEDB 2.0 @ LMMD
contrast agent BR1
(SFZCNBIFKDRMGX-UHFFFAOYSA-N)
Structure
SMILES
FS(F)(F)(F)(F)F
Type(s)
Approved
ATC code(s)
V08DA05
Molecular Formula:
F6S
Molecular Weight:
146.055
Log P:
3.1694
Hydrogen Bond Acceptor:
0
Hydrogen Bond Donor:
0
TPSA:
25.3
CAS Number(s):
2551-62-4
Synonym(s)
1.
contrast agent BR1
2.
SonoVue
External Link(s)
MeSHC420843
PubChem Compound17358
ChEBI30496
CHEMBLCHEMBL1796998
DrugBankDB11104
DrugCentral4039
KEGGdr:D05962
ZINC245224194
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1NauseaFAERS: 14
Canada Vigilance: 2
Canada Vigilance
SIDER
US FAERS
2Drug ineffectiveFAERS: 12US FAERS
3HypersensitivityFAERS: 9SIDER
US FAERS
4VomitingFAERS: 9US FAERS
5Unresponsive to stimuliFAERS: 8US FAERS
6Cardiac ArrestFAERS: 6US FAERS
7HypotensionFAERS: 6SIDER
US FAERS
8TachycardiaFAERS: 6US FAERS
9Abdominal PainFAERS: 5SIDER
US FAERS
10Back PainFAERS: 5SIDER
US FAERS
11Contrast media reactionFAERS: 5US FAERS
12DizzinessFAERS: 5SIDER
US FAERS
13FlushingFAERS: 5
Canada Vigilance: 2
Canada Vigilance
SIDER
US FAERS
14CyanosisFAERS: 4US FAERS
15MalaiseFAERS: 4US FAERS
16No adverse eventFAERS: 4US FAERS
17Product reconstitution quality issueFAERS: 4US FAERS
18PruritusFAERS: 4SIDER
US FAERS
19Respiratory arrestFAERS: 4US FAERS
20Anaphylactic shockFAERS: 3SIDER
US FAERS
21Anaphylactoid ReactionFAERS: 3SIDER
US FAERS
22Blood pressure immeasurableFAERS: 3US FAERS
23BradycardiaFAERS: 3US FAERS
24ErythemaFAERS: 3US FAERS
25Feeling abnormalFAERS: 3US FAERS
26HeadacheFAERS: 3SIDER
US FAERS
27SyncopeFAERS: 3US FAERS
28UrticariaFAERS: 3US FAERS
29Ventricular FibrillationFAERS: 3US FAERS
30Visual ImpairmentFAERS: 3US FAERS
31WheezingFAERS: 3US FAERS
32Chest discomfortFAERS: 2SIDER
US FAERS
33ChillsFAERS: 2US FAERS
34Cold sweatFAERS: 2US FAERS
35EpilepsyFAERS: 2US FAERS
36FatigueFAERS: 2SIDER
US FAERS
37Feeling ColdFAERS: 2US FAERS
38Muscle tightnessFAERS: 2US FAERS
39PainFAERS: 2SIDER
US FAERS
40Product physical issueFAERS: 2US FAERS
41Pulmonary EmbolismFAERS: 2US FAERS
42Respiratory distressFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
43Sudden deathFAERS: 2US FAERS
44TachyarrhythmiaFAERS: 2US FAERS
45TremorFAERS: 2US FAERS
46Abdominal discomfortFAERS: 1US FAERS
47Acute respiratory failureFAERS: 1US FAERS
48Agonal rhythmFAERS: 1US FAERS
49AngioedemaFAERS: 1US FAERS
50AnxietyFAERS: 1US FAERS
51AstheniaFAERS: 1SIDER
US FAERS
52AsthmaFAERS: 1US FAERS
53Burning sensationFAERS: 1US FAERS
54Cerebral InfarctionFAERS: 1US FAERS
55Cerebrovascular accidentFAERS: 1US FAERS
56Chest PainFAERS: 1SIDER
US FAERS
57Contrast media allergyFAERS: 1US FAERS
58Depressed Level of ConsciousnessFAERS: 1US FAERS
59Drug administration errorFAERS: 1US FAERS
60Drug effect incompleteFAERS: 1US FAERS
61DysgeusiaFAERS: 1SIDER
US FAERS
62Ear discomfortFAERS: 1US FAERS
63Eye painFAERS: 1US FAERS
64Facial paralysisFAERS: 1US FAERS
65Feeling jitteryFAERS: 1US FAERS
66HemiparesisFAERS: 1US FAERS
67IncoherentFAERS: 1US FAERS
68Kounis SyndromeFAERS: 1US FAERS
69Lip swellingFAERS: 1US FAERS
70Livedo ReticularisFAERS: 1US FAERS
71Multiple SclerosisFAERS: 1US FAERS
72Myocardial InfarctionFAERS: 1SIDER
US FAERS
73NeuralgiaFAERS: 1US FAERS
74PallorFAERS: 1US FAERS
75PalpitationsFAERS: 1US FAERS
76PresyncopeFAERS: 1US FAERS
77Procalcitonin increasedFAERS: 1US FAERS
78Product physical consistency issueFAERS: 1US FAERS
79SepsisFAERS: 1US FAERS
80SomnolenceFAERS: 1US FAERS
81Throat clearingFAERS: 1US FAERS
82TrismusFAERS: 1US FAERS
83Upper airway obstructionFAERS: 1US FAERS
84White blood cell count decreasedFAERS: 1US FAERS
85Acute Coronary SyndromeSIDER
86Blood glucose increasedSIDER
87BronchospasmCanada Vigilance: 1Canada Vigilance
88DermatitisSIDER
89Gastrointestinal PainSIDER
90Injection Site ReactionSIDER
91PharyngitisSIDER
92Sinus headacheSIDER
93nervous system disorderSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.